Comparing the efficacy in reducing dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride to a commercial sensitive toothpaste containing 2% potassium ion: an eight-week clinical study on Canadian adults.
OBJECTIVE
This paper presents the results of one of two eight-week dentin hypersensitivity clinical studies in which the efficacy of a novel toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP) was compared to that of a benchmark commercial toothpaste containing 2% potassium ion, dosed as 3.75% potassium chloride, and 1450 ppm fluoride as sodium fluoride (NaF).


METHODS
An eight-week clinical study, with seventy-seven patients, was conducted in Mississauga, Canada using a double-blind, stratified, two-treatment design. Tactile sensitivity assessments, as well as air blast sensitivity assessments, were used to compare the efficacy of the two products.


RESULTS
This clinical study demonstrated that the new toothpaste, containing 8.0% arginine and 1450 ppm MFP in a calcium carbonate base, provided a significant reduction in dentin hypersensitivity when used over a period of eight weeks. The study also showed that this new arginine toothpaste provided significantly greater reductions (p < 0.05) in dentin hypersensitivity in response to tactile (16.2%, 22.4%, and 21.4%) and air blast (16.2%, 29.2%, and 63.4%) stimuli than the benchmark commercial toothpaste containing 2% potassium ion and 1450 ppm NaF in a silica base, after two, four, and eight weeks of product use, respectively.


CONCLUSIONS
A new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride, as sodium monofluorophosphate (MFP), provides significantly greater hypersensitivity relief (p < 0.05) compared to a commercial sensitive toothpaste containing 2% potassium ion after two, four, and eight weeks of product use.
Ayad
Farid
F
Canadian Clinical Research Center, Mississauga, Ontario, Canada.
Ayad
Nuhad
N
Zhang
Yun Po
YP
DeVizio
William
W
Cummins
Diane
D
Mateo
Luis R
LR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000388:Air; D001120:Arginine / Q000008:administration & dosage / Q000627:therapeutic use*; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000517:prevention & control*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005459:Fluorides / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009864:Ontario; D010710:Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D011188:Potassium / Q000627:therapeutic use*; D011189:Potassium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D012822:Silicon Dioxide; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000627:therapeutic use; D014100:Toothpastes / Q000627:therapeutic use*; D014110:Touch; D016896:Treatment Outcome; D055815:Young Adult
D004338:Drug Combinations; D010710:Phosphates; D014100:Toothpastes; C012980:fluorophosphate; D011189:Potassium Chloride; D012822:Silicon Dioxide; D012969:Sodium Fluoride; D001120:Arginine; D002119:Calcium Carbonate; D005459:Fluorides; D011188:Potassium